Entera Q2 2026 earnings: Phase 3 preparation widened the loss

Entera Bio (NASDAQ: ENTX) reported no revenue in Q2 2026, unchanged from Q2 2025, while basic and diluted EPS fell to -$0.14 from -$0.06. Net loss widened to $7.3 million as Phase 3 preparation increased research spending and a non-cash warrant remeasurement added $2.7 million of financial expense. A $275 million private placement completed after quarter-end materially expanded the company’s funding position.

Core financial results

Entera remains a clinical-stage biotechnology company without product revenue. Q2 operating expenses rose by $1.9 million year over year, primarily because R&D spending more than doubled as the company prepared the EB613 Phase 3 program and conducted work under its OPKO Health collaboration.

The net loss increased more sharply than the operating loss because of the warrant-related accounting charge.

Pipeline and program updates

EB613 advances toward a registrational study

The FDA accepted Entera’s plan for a single randomized, double-blind, placebo-controlled Phase 3 trial enrolling approximately 750 postmenopausal women with osteoporosis. The primary endpoint will measure the percentage change from baseline in total hip bone mineral density at Month 12.

The proposed NDA package will also include a scientific bridge to Forteo under the 505(b)(2) pathway and a bone biopsy sub-study. Patients will continue to be followed for 24 months under a separate open-label extension protocol, with data through 18 months expected to form part of the NDA’s 120-day safety update.

Entera also presented Phase 1 results showing that its single-tablet EB613 formulation produced pharmacokinetic and pharmacodynamic profiles comparable to the multi-tablet formulation used in Phase 2 and to Forteo. These data support using the single-tablet formulation in Phase 3.

EB612 remains in preclinical development

EB612, an oral long-acting PTH(1-34) replacement candidate for hypoparathyroidism, generated preclinical results across rat, minipig and non-human primate models. Single oral doses produced sustained increases in serum calcium lasting approximately three days, with no safety concerns identified in those studies.

Entera and OPKO are conducting IND-enabling work and intend to file an investigational new drug application in the first half of 2027.

EB618 development depends on additional OPKO data

In non-human primates, the oral GLP-1/glucagon candidate EB618 demonstrated dose-proportional exposure and effects on post-meal blood glucose across three tablet strengths. It was well tolerated at doses more than ten times above the anticipated clinical range.

Entera has not committed to a clinical start date. The company expects to evaluate the program after analyzing OPKO’s Phase 1 studies of an injectable oxyntomodulin candidate.

Non-cash warrant accounting widened the gap between operating and net loss

Entera’s $4.6 million operating loss primarily reflected R&D and administrative spending, but its net loss reached $7.3 million. The difference was largely attributable to $2.7 million of non-cash financial expense from the fair-value remeasurement of pre-funded warrants issued in the April 2026 private placement.

This accounting item did not represent a corresponding quarterly cash outflow. However, it can introduce volatility into reported net income as long as the warrants remain classified as a financial liability. Separately, the underlying operating loss also increased as EB613 moved closer to Phase 3.

Liquidity and balance sheet

At June 30, Entera held $11.3 million in cash and cash equivalents, up from $7.1 million at the end of 2025. It also held $7.1 million of restricted cash, primarily designated for the OPKO collaboration.

The quarter-end balance sheet did not include the subsequent $275 million private placement. That financing closed in July and generated approximately $275 million in gross proceeds before fees and offering expenses.

The increase in liabilities included a $9.6 million pre-funded warrant liability. The July financing is expected to fund the EB613 registrational program through topline results and an anticipated NDA submission, while also supporting EB612’s clinical advancement with OPKO.

Guidance and development milestones

Entera’s outlook focuses on clinical execution rather than revenue or earnings targets. The principal milestones are the start and completion of the EB613 Phase 3 study, the EB612 IND filing and the expected extension of the company’s operating runway.

These timelines remain development targets rather than completed regulatory milestones.

Recent insider transactions

The supplied insider-transaction records show four stock awards followed by six reported purchases. The separate six-month summary listed zero purchases, creating a discrepancy with the transaction-level data; the records below are therefore presented without drawing conclusions about insider sentiment.

The six purchases shown had a combined reported value of $98,650. The transaction data did not provide enough consistent information to reconcile them with the zero-purchase six-month summary.

Risks investors should watch

• EB613 execution risk: The registrational study had not started as of the earnings release. Enrollment, trial conduct and data quality could affect the targeted second-half 2028 topline timeline.
• Clinical and regulatory uncertainty: FDA alignment on the Phase 3 design does not guarantee successful trial results or approval of a future NDA. The agency will still review the complete clinical and safety package.
• Higher development spending: R&D expense more than doubled as Entera prepared EB613 for Phase 3 and advanced collaboration activities. Further pipeline progress will require sustained spending.
• Reliance on external development work: The timing of EB612 and EB618 depends partly on collaboration and study activities involving OPKO.
• Accounting volatility from warrants: Fair-value changes in warrant liabilities can create sizable non-cash financial expenses and cause reported net loss to diverge from operating performance.

Summary

Entera’s Q2 2026 results reflected a transition toward late-stage development: R&D spending increased, and a non-cash warrant charge amplified the net loss. The central operating focus is now the planned late-2026 start of EB613’s Phase 3 trial, supported by the post-quarter $275 million financing. Investors will need to monitor Phase 3 execution, the durability of the projected runway and progress toward the EB612 IND filing.